402 related articles for article (PubMed ID: 8666572)
21. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
[TBL] [Abstract][Full Text] [Related]
22. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.
Seedat S; Stein DJ
Int Clin Psychopharmacol; 1999 Nov; 14(6):353-6. PubMed ID: 10565802
[TBL] [Abstract][Full Text] [Related]
23. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Maiti R; Mishra A; Srinivasan A; Mishra BR
Acta Psychiatr Scand; 2023 Jul; 148(1):19-31. PubMed ID: 37177823
[TBL] [Abstract][Full Text] [Related]
25. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
26. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
[TBL] [Abstract][Full Text] [Related]
27. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
28. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
29. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
30. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.
Husted DS; Shapira NA; Murphy TK; Mann GD; Ward HE; Goodman WK
J Psychiatr Res; 2007; 41(3-4):332-7. PubMed ID: 16860338
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
[TBL] [Abstract][Full Text] [Related]
32. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Sun TF; Lin PY; Wu CK
Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
[TBL] [Abstract][Full Text] [Related]
33. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors.
Gautam M
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):369-377. PubMed ID: 37335203
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
[TBL] [Abstract][Full Text] [Related]
35. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
Mohr N; Vythilingum B; Emsley RA; Stein DJ
Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
[TBL] [Abstract][Full Text] [Related]
36. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
38. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
Fitzgerald KD; Stewart CM; Tawile V; Rosenberg DR
J Child Adolesc Psychopharmacol; 1999; 9(2):115-23. PubMed ID: 10461822
[TBL] [Abstract][Full Text] [Related]
39. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
40. Update on pharmacologic management of OCD: agents and augmentation.
McDougle CJ
J Clin Psychiatry; 1997; 58 Suppl 12():11-7. PubMed ID: 9393391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]